Osteoporosis: From Molecular Mechanisms to Therapies 3.0

Osteoporosis is a common skeletal disorder that occurs as a result of an imbalance between bone resorption and bone formation, with bone breakdown exceeding bone building. Bone resorption inhibitors, e.g., bisphosphonates, have been designed to treat osteoporosis. Teriparatide, an anabolic agent, stimulates bone formation and corrects the characteristic changes in the trabecular microarchitecture. However, these drugs are associated with significant side effects. It is therefore crucial that we continue to research the pathogenesis of osteoporosis and seek novel modes of therapy. This editorial summarizes and discusses the themes of the six articles published in our Special Issue Osteoporosis: From Molecular Mechanisms to Therapies 3.0 , a continuation of our 2020 Special Issue Osteoporosis: From Molecular Mechanisms to Therapies . These Special Issues detail important global scientific findings that contribute to our current understanding of osteoporosis.

Automated summary

Osteoporosis is a common skeletal disorder caused by an imbalance between bone resorption and bone formation. Current treatments include bone resorption inhibitors and anabolic agents, which can have significant side effects, highlighting the importance of further research into the pathogenesis of the disease and the development of novel therapies.